Immuneering Corp. (IMRX)
3.73
-0.08
(-2.10%)
USD |
NASDAQ |
Oct 23, 16:00
3.56
-0.17
(-4.56%)
After-Hours: 07:24
Immuneering Net Income (Quarterly) : -17.27M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -17.27M |
| March 31, 2026 | -13.46M |
| December 31, 2025 | -11.58M |
| September 30, 2025 | -14.96M |
| June 30, 2025 | -14.43M |
| March 31, 2025 | -15.05M |
| December 31, 2024 | -18.05M |
| September 30, 2024 | -14.60M |
| June 30, 2024 | -14.08M |
| March 31, 2024 | -14.31M |
| December 31, 2023 | -15.08M |
| September 30, 2023 | -12.60M |
| June 30, 2023 | -12.19M |
| Date | Value |
|---|---|
| March 31, 2023 | -13.60M |
| December 31, 2022 | -13.25M |
| September 30, 2022 | -12.84M |
| June 30, 2022 | -11.53M |
| March 31, 2022 | -12.90M |
| December 31, 2021 | -10.78M |
| September 30, 2021 | -8.534M |
| June 30, 2021 | -7.988M |
| March 31, 2021 | -6.230M |
| December 31, 2020 | -5.836M |
| September 30, 2020 | -4.399M |
| June 30, 2020 | -3.604M |
| March 31, 2020 | -3.201M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 17.27M |
| EPS Diluted (Quarterly) | -0.2669 |
| Enterprise Value | 95.05M |
| Earnings Yield | -27.66% |
| Normalized Earnings Yield | -27.66 |